Vifor Pharma Secures EU Approval for FILSPARI® in IgA Nephropathy Treatment
Vifor Pharma AG has secured standard EU approval for FILSPARI (sparsentan) to treat IgA Nephropathy, a significant milestone for the company in the competitive IgAN treatment landscape.
2 minutes to read